Overview

Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

Status:
Enrolling by invitation

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This is a phase I trial evaluating the maximum tolerated dose, safety and efficiency of Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD), injected into the resection cavity of patients with recurrent glioblastoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

CHA University

Collaborator:

Ajou University School of Medicine